|1.||Mack, R J: 3 articles (04/2002 - 12/2000)|
|2.||Verlinden, M: 3 articles (09/2001 - 04/2000)|
|3.||Dettmer, A: 2 articles (04/2002 - 12/2000)|
|4.||Riff, D: 2 articles (04/2002 - 09/2001)|
|5.||Brinkhoff, H: 2 articles (04/2002 - 12/2000)|
|6.||Talley, N J: 2 articles (09/2001 - 12/2000)|
|7.||Takanashi, Hisanori: 1 article (06/2009)|
|8.||Cynshi, Osamu: 1 article (06/2009)|
|9.||Schmitt, B: 1 article (08/2002)|
|10.||Inauen, W: 1 article (08/2002)|
|1.||Gastroesophageal Reflux (GERD)
04/01/2002 - "To assess the efficacy of four different doses of ABT-229 (1.25 mg, 2.5 mg, 5 mg, 10 mg b.d.) compared to placebo in the treatment of gastro-oesophageal reflux disease, and to determine its safety in patients with gastro-oesophageal reflux disease. "
08/01/2002 - "ABT-229 is able to reduce slightly, but significantly, acid reflux in patients with gastro-oesophageal reflux disease. "
08/01/2002 - "The effect of ABT-229, a new macrolide with no antibacterial activity, on gastro-oesophageal reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease was investigated. "
04/01/2002 - "ABT-229 appeared to be well tolerated and safe in total daily doses up to 20 mg. ABT-229 appears to have limited, if any, clinical utility in the treatment of gastro-oesophageal reflux disease."
04/01/2000 - "The value of ABT-229 in the treatment of GERD appears to be limited."
12/01/2000 - "ABT-229 was of no value for relief of symptoms in functional dyspepsia, compared with placebo."
12/01/2000 - "We aimed to test the efficacy of the motilin agonist ABT-229 in functional dyspepsia patients with and without delayed gastric emptying. "
06/05/2009 - "Since ABT-229 (a first generation of motilin receptor agonist) had failed to demonstrate symptomatic relief in functional dyspepsia and diabetic gastroparesis, there is a controversy for which of prokinetics or relaxants is clinically beneficial. "
04/01/2002 - "In a double-blind, multicentre study, 324 patients with heartburn were randomized to receive four different doses of ABT-229 or placebo for 8 weeks. "
12/01/2000 - "Excluding patients with any baseline heartburn (total remaining n=240), ABT-229 10 mg was inferior to placebo in relief of upper abdominal discomfort. "
09/01/2001 - "The severity of bloating, postprandial nausea, epigastric discomfort, heartburn, and acid regurgitation worsened dose dependently in a greater number of patients receiving ABT-229 than placebo. "